Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;4(2):289-96.
doi: 10.2147/vhrm.s930.

Early detection and management of the high-risk patient with elevated blood pressure

Affiliations
Review

Early detection and management of the high-risk patient with elevated blood pressure

Cristina Sierra et al. Vasc Health Risk Manag. 2008.

Abstract

Severe or important blood pressure elevations are associated with the risk of cardiovascular disease. However, a significant proportion of myocardial infarctions and strokes occur in subjects with only slight elevations or even with normal blood pressure. Both the coexistence of other cardiovascular risk factors, such as diabetes or dyslipidemia, or those recently recognized, such as elevations of C-reactive protein or abdominal obesity and metabolic syndrome, or the presence of target organ damage, such as microalbuminuria, left ventricular hypertrophy, mild renal dysfunction or increased intima-media thickness, all indicate the existence of a high cardiovascular risk in mild hypertensives or in subjects with normal or high-normal blood pressure. Unfortunately, these high-risk patients are often not recognized and thus under-treated. The 2003 European Societies of Hypertension and Cardiology guidelines emphasize the importance of a complete risk assessment and stratification in subjects at all blood pressure categories. The search for other cardiovascular risk factors and target organ damage should be encouraged. Identification of these high-risk patients may allow an earlier indication for antihypertensive treatment and for correction of all cardiovascular risk factors. The objective would be to impair the progression or to induce the regression of silent vascular damage before a clinical event develops.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anderson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow-up study after two decades. BMJ. 1998;317:167–71. - PMC - PubMed
    1. ARIC Investigators. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in the Communities (ARIC) study. Am J Epidemiol. 1997;146:483–94. - PubMed
    1. Badimon JJ, Fuster V, Chesebro JH, et al. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(Suppl):II3–16. - PubMed
    1. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–61. - PubMed
    1. Blake GJ, Rifai N, Buring JE, et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993–9. - PubMed

MeSH terms